SCHEMBL7220276

SCHEMBL7220276

Cn1cc(C(=O)O)c(=O)c2c3ccc(N4CCN(c5ccc(F)cc5)CC4)c(F)c3ncc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RPS6KB1 P23443 1/20 0.42
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 5/20 0.39
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 3/20 0.37
POLB P06746 2/20 0.36
HSP90AA1 P07900 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
THRB P10828 2/20 0.36
DRD3 P35462 1/20 0.36
USP2 O75604 1/20 0.35
PTPN7 P35236 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7227944 0.90 RPS6KB1 (0.44) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7219802 0.89 ALDH1A1 (0.41) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6974364 0.89 LMNA (0.41) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7220757 0.89 ALDH1A1 (0.41) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL7227611 0.88 DRD3 (0.46) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL7221946 0.88 RPS6KB1 (0.47) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7226525 0.88 LMNA (0.45) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7227712 0.87 LMNA (0.44) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7228069 0.87 LMNA (0.37) LMNAMEN1KMT2ARPS6KB1KDM4E
SCHEMBL7226972 0.86 LMNA (0.35) LMNAMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6566362-B2 Use as topical antibiotics AVENTIS PHARMA S.A. (FR) 2003-05-20 US disclosed
US-20020137741-A1 Benzo[f]naphthyridine derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. (FR) 2002-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137741-A1 Benzo[f]naphthyridine derivatives, their preparation and compositions containing them KCNQ2, KCNQ1, KCNQ4 LMNA 182/4885MEN1 2544/4885KMT2A 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.